chlordiazepoxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	594	58-25-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: chlordiazepoxide chlordiazepoxide hydrochloride chloridazepoxide methaminodiazepoxide chlordiazepoxid chlorodiazepoxide chlordiazepoxide HCl	An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. Molecular weight: 299.76 Formula: C16H14ClN3O CLOGP: 3.79 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 53.14 ALOGS: -4.18 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

chlordiazepoxide
chlordiazepoxide hydrochloride
chloridazepoxide
methaminodiazepoxide
chlordiazepoxid
chlorodiazepoxide
chlordiazepoxide HCl

An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.

Molecular weight: 299.76
Formula: C16H14ClN3O
CLOGP: 3.79
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 53.14
ALOGS: -4.18
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
50	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	14.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.25 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.37 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.06 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 24, 1960	FDA	VALEANT PHARM INTL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral venous thrombosis	214.89	22.72	43	2876	1828	50600377
Drug abuse	95.64	22.72	53	2866	59793	50542412
Hyperreflexia	90.84	22.72	26	2893	5092	50597113
Bradyphrenia	90.44	22.72	27	2892	6125	50596080
Thalamic infarction	80.56	22.72	15	2904	432	50601773
Drug interaction	72.13	22.72	72	2847	199549	50402656
Sopor	56.41	22.72	26	2893	19853	50582352
Toxicity to various agents	47.95	22.72	60	2859	212439	50389766
Drug withdrawal syndrome	47.78	22.72	25	2894	25056	50577149
Disorientation	47.41	22.72	28	2891	35456	50566749
Clonus	47.25	22.72	15	2904	4160	50598045
Apraxia	46.95	22.72	12	2907	1533	50600672
Intentional product misuse	42.71	22.72	29	2890	46705	50555500
Perseveration	42.17	22.72	8	2911	255	50601950
Completed suicide	39.30	22.72	43	2876	131846	50470359
Confusional state	37.97	22.72	50	2869	185878	50416327
Slow response to stimuli	37.78	22.72	9	2910	860	50601345
Dyskinesia	37.24	22.72	22	2897	27839	50574366
Muscle twitching	34.08	22.72	17	2902	15414	50586791
Derailment	31.56	22.72	5	2914	53	50602152
Overdose	28.79	22.72	32	2887	99695	50502510
Abdominal tenderness	28.67	22.72	12	2907	7268	50594937
Disturbance in attention	27.64	22.72	19	2900	31167	50571038
Abnormal behaviour	27.52	22.72	16	2903	19642	50582563
Cognitive disorder	25.92	22.72	21	2898	44102	50558103
Psychomotor retardation	25.60	22.72	9	2910	3409	50598796
Serotonin syndrome	24.15	22.72	16	2903	24697	50577508
Myoclonus	23.55	22.72	13	2906	14457	50587748
Product use in unapproved indication	23.36	22.72	31	2888	115788	50486417
Body temperature increased	22.95	22.72	17	2902	31324	50570881

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	165.97	29.30	81	1452	79802	29493192
Ventricular tachyarrhythmia	109.21	29.30	18	1515	280	29572714
Toxicity to various agents	101.01	29.30	78	1455	173583	29399411
Delusion of replacement	63.14	29.30	10	1523	119	29572875
Overdose	46.36	29.30	36	1497	79783	29493211
Shoshin beriberi	45.40	29.30	7	1526	69	29572925
Completed suicide	32.53	29.30	31	1502	90215	29482779
Hypoglycaemia	30.63	29.30	23	1510	48323	29524671

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	237.14	22.94	128	3758	132246	64362600
Cerebral venous thrombosis	201.54	22.94	43	3843	2398	64492448
Toxicity to various agents	116.01	22.94	125	3761	363388	64131458
Hyperreflexia	85.26	22.94	27	3859	7121	64487725
Bradyphrenia	77.98	22.94	27	3859	9379	64485467
Sopor	68.08	22.94	34	3852	29627	64465219
Thalamic infarction	66.26	22.94	15	3871	1097	64493749
Completed suicide	64.08	22.94	73	3813	224341	64270505
Delusion of replacement	59.78	22.94	10	3876	145	64494701
Disorientation	57.65	22.94	38	3848	55790	64439056
Drug interaction	51.57	22.94	84	3802	361999	64132847
Overdose	47.33	22.94	53	3833	159513	64335333
Intentional product misuse	44.52	22.94	36	3850	72259	64422587
Shoshin beriberi	44.34	22.94	7	3879	69	64494777
Drug withdrawal syndrome	44.19	22.94	26	3860	31265	64463581
Clonus	41.11	22.94	15	3871	6052	64488794
Apraxia	40.73	22.94	12	3874	2483	64492363
Perseveration	38.84	22.94	8	3878	374	64494472
Alcoholism	37.01	22.94	12	3874	3405	64491441
Agoraphobia	35.98	22.94	8	3878	539	64494307
Cardio-respiratory arrest	34.98	22.94	36	3850	98357	64396489
Muscle twitching	32.78	22.94	18	3868	18980	64475866
Abnormal behaviour	32.55	22.94	22	3864	33600	64461246
Confusional state	32.33	22.94	57	3829	261087	64233759
Slow response to stimuli	32.13	22.94	9	3877	1556	64493290
Derailment	29.99	22.94	5	3881	71	64494775
Dyskinesia	29.41	22.94	22	3864	39366	64455480
Dementia	28.64	22.94	17	3869	20749	64474097
Delirium	25.82	22.94	26	3860	69168	64425678
Abdominal tenderness	25.22	22.94	12	3874	9393	64485453
Cognitive disorder	24.89	22.94	23	3863	55064	64439782
Withdrawal syndrome	24.25	22.94	16	3870	23476	64471370

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05BA02	NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Benzodiazepine derivatives
FDA CS	M0002356	Benzodiazepines
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:60807	anaesthestic adjuvant
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D006993	Hypnotics and Sedatives
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
FDA EPC	N0000175694	Benzodiazepine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alcohol withdrawal delirium	indication	8635005
Irritable bowel syndrome	indication	10743008	DOID:9778
Peptic ulcer	indication	13200003	DOID:750
Anxiety	indication	48694002
General anesthesia	indication	50697003
Severe anxiety (panic)	indication	80583007
Alcohol withdrawal syndrome	indication	191480000
Mixed anxiety and depressive disorder	indication	231504006
Local anesthesia	indication	386761002
Preoperative Anxiety	indication
Pre-Op Apprehension	indication
Anxiety associated with Menopause	indication
Panic disorder	off-label use	371631005	DOID:594
Tension-type headache	off-label use	398057008
Brain damage	contraindication	2470005
Hyperlipoproteinemia	contraindication	3744001	DOID:1168
Hypocalcemia	contraindication	5291005
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Sinus tachycardia	contraindication	11092001
Hypercholesterolemia	contraindication	13644009
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of lung	contraindication	19829001	DOID:850
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Orthostatic hypotension	contraindication	28651003
Atony of colon	contraindication	29479008
Torsades de pointes	contraindication	31722008
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Chloasma	contraindication	36209000
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Body fluid retention	contraindication	43498006
Hyperactive behavior	contraindication	44548000
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Thrombosis of retinal vein	contraindication	46085004
Humoral hypercalcemia of malignancy	contraindication	47709007
Chronic heart failure	contraindication	48447003
Dementia	contraindication	52448006
Hepatic porphyria	contraindication	55056006	DOID:3133
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Thrombophlebitis	contraindication	64156001	DOID:3875
Ulcerative colitis	contraindication	64766004	DOID:8577
Intermenstrual bleeding - irregular	contraindication	64996003
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Sleep apnea	contraindication	73430006	DOID:0050847
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Chronic idiopathic constipation	contraindication	82934008
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Epilepsy	contraindication	84757009	DOID:1826
Breast lump	contraindication	89164003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Uterine leiomyoma	contraindication	95315005	DOID:13223
Prolonged QT interval	contraindication	111975006
Hypoalbuminemia	contraindication	119247004
Gastrointestinal obstruction	contraindication	126765001
Deep venous thrombosis	contraindication	128053003
Endometriosis	contraindication	129103003
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Mammography abnormal	contraindication	168750009
Bipolar affective disorder, current episode manic	contraindication	191618007
Asthma	contraindication	195967001	DOID:2841
Cerebrovascular accident	contraindication	230690007
Myocardial dysfunction	contraindication	233928007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Endometrial carcinoma	contraindication	254878006	DOID:2871
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Syncope	contraindication	271594007
Chorea	contraindication	271700006
Drowsy	contraindication	271782001
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Functional visual loss	contraindication	313165001
Severe chronic obstructive pulmonary disease	contraindication	313299006
Malignant tumor of ovary	contraindication	363443007	DOID:2394
Thromboembolic disorder	contraindication	371039008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Obesity	contraindication	414916001	DOID:9970
Estrogen receptor positive tumor	contraindication	416053008
Myocardial infarction in recovery phase	contraindication	418044006
Porphyria	contraindication	418470004
Family history of malignant neoplasm of breast	contraindication	429740004
Congenital long QT syndrome	contraindication	442917000
Hypertensive urgency	contraindication	443482000
Carcinoma of female breast	contraindication	447782002
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.79	Basic
pKa2	4.13	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
GABA-A receptor alpha-2/beta-3/gamma-2	Ion channel	P18507 P28472 P47869	GBRG2_HUMAN GBRB3_HUMAN GBRA2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.34	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2	Ion channel	P18507 P28472 P34903	GBRG2_HUMAN GBRB3_HUMAN GBRA3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.56	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.50	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	6.25	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2	Ion channel	P14867 P18507 P28472	GBRA1_HUMAN GBRG2_HUMAN GBRB3_HUMAN		Ki	6.25	CHEMBL
Cholecystokinin receptor	GPCR	P32238 P32239	CCKAR_HUMAN GASR_HUMAN		IC50	4	CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	6.68	DRUG MATRIX
Thyrotropin-releasing hormone receptor	GPCR	P34981	TRFR_HUMAN		Ki	6.54	WOMBAT-PK
Thyrotropin-releasing hormone receptor	GPCR		TRFR_RAT	ANTAGONIST	Ki	4.82	IUPHAR
Cholinesterase	Enzyme		CHLE_HORSE		Ki	6.52	CHEMBL
Thyrotropin-releasing hormone receptor	GPCR		TRFR_MOUSE	ANTAGONIST	Ki	4.70	IUPHAR
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		IC50	6.70	CHEMBL
GABA-A receptor; anion channel	Ion channel		GBRA1_BOVIN GBRB1_BOVIN GBRA2_BOVIN GBRA3_BOVIN GBRA4_BOVIN GBRG2_BOVIN		IC50	6.10	CHEMBL
Cholecystokinin receptor	GPCR		CCKAR_RAT GASR_RAT		IC50	4	CHEMBL
Acetylcholinesterase	Enzyme		ACES_ELEEL		Ki	4.30	CHEMBL
Translocator protein	Membrane receptor		TSPO_RAT		Ki	6.36	CHEMBL

External reference:

ID	Source
4017780	VUID
N0000146141	NUI
D00267	KEGG_DRUG
438-41-5	SECONDARY_CAS_RN
203173	RXNORM
4017780	VANDF
4017808	VANDF
C0008188	UMLSCUI
CHEBI:3611	CHEBI
CHEMBL451	ChEMBL_ID
DB00475	DRUGBANK_ID
CHEMBL1200703	ChEMBL_ID
D002707	MESH_DESCRIPTOR_UI
2712	PUBCHEM_CID
3370	IUPHAR_LIGAND_ID
1049	INN_ID
6RZ6XEZ3CR	UNII
3903	MMSL
4409	MMSL
4410	MMSL
d00189	MMSL
001454	NDDF
001455	NDDF
372866006	SNOMEDCT_US
40601003	SNOMEDCT_US
82746003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Librax	HUMAN PRESCRIPTION DRUG LABEL	2	0187-4100	CAPSULE	5 mg	ORAL	NDA	18 sections
Not applicable	HUMAN PRESCRIPTION DRUG LABEL	2	0276-0500	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0211	TABLET, FILM COATED	5 mg	ORAL	ANDA	24 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0277	TABLET, FILM COATED	10 mg	ORAL	ANDA	24 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0033	CAPSULE	10 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0158	CAPSULE	5 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0159	CAPSULE	25 mg	ORAL	ANDA	18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	10135-622	CAPSULE	5 mg	ORAL	UNAPPROVED DRUG OTHER	17 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0164	CAPSULE	25 mg	ORAL	ANDA	19 sections
chlordiazepoxide hydrochloride and clidinium bromide	HUMAN PRESCRIPTION DRUG LABEL	2	23155-808	CAPSULE	5 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42494-409	CAPSULE	5 mg	ORAL	NDA authorized generic	20 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	42571-302	TABLET	12.50 mg	ORAL	ANDA	24 sections
Chlordiazepoxide and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	42571-303	TABLET	25 mg	ORAL	ANDA	24 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42582-300	CAPSULE	5 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42582-301	CAPSULE	5 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-561	CAPSULE, GELATIN COATED	5 mg	ORAL	ANDA	21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-562	CAPSULE, GELATIN COATED	10 mg	ORAL	ANDA	21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-562	CAPSULE, GELATIN COATED	10 mg	ORAL	ANDA	21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-563	CAPSULE, GELATIN COATED	25 mg	ORAL	ANDA	21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-563	CAPSULE, GELATIN COATED	25 mg	ORAL	ANDA	21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-564	CAPSULE, GELATIN COATED	5 mg	ORAL	ANDA	20 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-564	CAPSULE, GELATIN COATED	5 mg	ORAL	ANDA	20 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-565	CAPSULE, GELATIN COATED	10 mg	ORAL	ANDA	20 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-565	CAPSULE, GELATIN COATED	10 mg	ORAL	ANDA	20 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-566	CAPSULE, GELATIN COATED	25 mg	ORAL	ANDA	20 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-566	CAPSULE, GELATIN COATED	25 mg	ORAL	ANDA	20 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-046	CAPSULE	25 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-046	CAPSULE	25 mg	ORAL	ANDA	19 sections